Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests to an inspiring agenda of some of the most up to date news of our funded...
Learn more
Sisters fundraise and raise awareness for Cure Parkinson’s
Sisters Susanna and Eliza Kidd had a super summer of fundraising for Cure Parkinson’s!
The AND-PD Trial
This study (ANxiety with or without depressive features in Parkinson’s Disease ‘AND-PD’) is an observational and imaging study where people at different stages of Parkinson’s will be assessed and followed for one year. This study, led by Professor Anette Schrag, is looking to recruit around…
The Anle138b Trial
This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. This trial, it is hoped, will slow-down…
PD Frontline
As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of developing Parkinson’s. PD Frontline is a remote study offering online genetic testing for people with Parkinson’s,…
The Bydureon (exenatide) phase 3 trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon (exenatide) phase 3 trial which is recruiting from six sites in the UK. This phase 3 clinical trial is testing the efficacy of exenatide in a large cohort of people with Parkinson’s and…